tirzepatide tachycardia Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring PSA: Tirzepatide Dosage and Resting

As a result, the incidence of atherosclerotic disease in patients on GLP-1 agonists will decline

However, the top specialists at Blue Fin Vision employ various approaches that may benefit certain patients: Acute Management: Immediate discontinuation of GLP-1 medication when NAION is confirmed Corticosteroid therapy in selected cases Comprehensive cardiovascular risk factor assessment Secondary Prevention: Aggressive management of vascular risk factors Blood pressure optimisation Aspirin therapy consideration Regular monitoring of the unaffected eye Risk Factors and Patient Selection Certain patient populations require particularly careful consideration before initiating GLP-1 therapy: High-Risk Patients: Individuals with pre-existing diabetic retinopathy Patients with poorly controlled diabetes and high HbA1c levels Those with cardiovascular risk factors Elderly patients Individuals with optic nerve head abnormalities The experienced team at Blue Fin Vision collaborates closely with endocrinologists and primary care physicians to ensure appropriate patient selection and monitoring protocols

Anandamide exerts a differential effect on human placenta before and after the onset of labor

By Alex Hao, Lumafield Ozempic and other glucagon-like peptide-1 (GLP-1) drugs have had a transformative effect on the health of millions of diabetes patients